Clinical trials for Cancer in United States

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)

Study ID: NCT06637423

Sponsor

Merck Sharp & Dohme LLC

Study to Assess the Feasibility of Stopping Prostate Cancer Treatment Early in Elderly Patients

Study ID: NCT06824818

Sponsor

University of Chicago

MK-7075 (Miransertib) in Proteus Syndrome

Study ID: NCT04316546

Sponsor

National Human Genome Research Institute (NHGRI)

Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response

Study ID: NCT03096418

Sponsor

University of Wisconsin, Madison

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

Study ID: NCT07185997

Sponsor

ArriVent BioPharma, Inc.

Post-Discharge Risk-Based Management in Patients Undergoing High-Risk Elective Major Cancer Operations (PRS II)

Study ID: NCT05454280

Sponsor

Fox Chase Cancer Center

Individualized Treatments in Adults With Relapsed/Refractory Cancers

Study ID: NCT06024603

Sponsor

Case Comprehensive Cancer Center

Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors

Study ID: NCT04751396

Sponsor

M.D. Anderson Cancer Center

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

Study ID: NCT06875310

Sponsor

Mirati Therapeutics Inc.

The Physiological Responses and Adaptation of Brown Adipose Tissue to Chronic Treatment With Beta3-Adrenergic Receptor Agonists

Study ID: NCT03049462

Sponsor

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)